Who are AL0704rP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): HDM 12 SQ-HDM, Cupressus arizonica, Allergovit Birch pollen, Staloral 300, tree 12 SQ-Bet, PURETHAL Birch, 20.000 AUM/ml.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/al0704rp.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

AL0704rP — Competitive Intelligence Brief

AL0704rP (AL0704rP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allergen immunotherapy. Area: Immunology / Allergy.

phase 3 Allergen immunotherapy Immunology / Allergy Biologic Live · refreshed every 30 min

Target snapshot

AL0704rP (AL0704rP) — Allergopharma GmbH & Co. KG. AL0704rP is an allergen immunotherapy designed to modulate immune tolerance to specific allergens through controlled exposure and immune desensitization.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AL0704rP TARGET	AL0704rP	Allergopharma GmbH & Co. KG	phase 3	Allergen immunotherapy
HDM 12 SQ-HDM	HDM 12 SQ-HDM	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	House dust mite allergens (Der p 1, Der p 2, Der f 1, Der f 2)
Cupressus arizonica	Cupressus arizonica	Laboratorios Leti, S.L.	marketed	Allergen immunotherapy
Allergovit Birch pollen	Allergovit Birch pollen	Royal Sussex County Hospital	marketed	Allergen immunotherapy
Staloral 300	Staloral 300	Medical University of Lodz	marketed	Allergen immunotherapy (sublingual tablet)	Grass pollen allergens (Phleum pratense and related species)
tree 12 SQ-Bet	tree 12 SQ-Bet	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy (sublingual tablet)	Tree pollen allergens (IgE cross-linking epitopes)
PURETHAL Birch, 20.000 AUM/ml	PURETHAL Birch, 20.000 AUM/ml	HAL Allergy	marketed	Allergen immunotherapy extract	Birch pollen allergens (Bet v 1 and related proteins)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allergen immunotherapy class)

Allergopharma GmbH & Co. KG · 8 drugs in this class
HAL Allergy · 2 drugs in this class
Medical University of Silesia · 2 drugs in this class
ALK-Abelló A/S · 2 drugs in this class
Laboratorios Leti, S.L. · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Royal Sussex County Hospital · 1 drug in this class
The University of Texas Medical Branch, Galveston · 1 drug in this class
University of Genova · 1 drug in this class
Anergis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AL0704rP — Competitive Intelligence Brief. https://druglandscape.com/ci/al0704rp. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab